Project Grant R01CA294307
- This $3,355,681 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) aims to evaluate the impact of accessible and scalable digital interventions to address co-occurring insomnia and depression in breast cancer survivors. The project will assess the efficacy of two evidence-based digital interventions, SHUTI and INTELLICARE, in treating these conditions both individually and through an adaptive approach that sequences the interventions based...
- This Project Grant award of $2,746,080, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), supports research on the effects of remotely-delivered cognitive behavioral stress management (R-CBSM) on cancer-accelerated aging in older, distressed breast cancer survivors. The project will enroll 192 breast cancer survivors within 3-12 months of completing initial treatment, some of whom received chemotherapy. Participants will undergo...
- This federal Project Grant award of $649,293 from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) aims to study healthcare utilization and outcomes across the cancer care continuum, with a focus on understanding the impact of social risk factors and screening among Latino patients. The 5-year project, awarded to Ochin, Inc., a nonprofit health IT collaborative in Oregon, will leverage a robust electronic health record database spanning over 2 million Latino...
- This NCI Early K99/R00 Project Grant from the National Cancer Institute's (NCI) Cancer Research Manpower (CFDA 93.398) program aims to refine and test the delivery of cognitive behavioral therapy for insomnia (CBT-I) to address insomnia and related symptoms in lung cancer survivors (LCS). The $224,968 award will fund a two-phase project. In the K99 phase, the grantee, Wake Forest University Health Sciences, will conduct stakeholder interviews and convene an advisory board to refine the CBT-I...
- This federal Project Grant award, totaling $696,140, was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program. The grant aims to test a digital psychoeducation-activation tool and implementation strategy, called ICAN DEPCARE, to improve uptake of evidence-based depression treatment among cancer patients. The project, led by The Trustees of Columbia University in the City of New York, will conduct a clinic-level cluster randomized...
- The National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, awarded a $1,338,648 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the University of Pittsburgh. The grant will fund a "Hybrid Type I Cluster Randomized Effectiveness-Implementation Trial of CARES" to address clinically significant levels of depression, pain, and fatigue experienced by over 18 million Americans living with cancer. The project aims to...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) provides $599,339 to the University of Miami to conduct a randomized clinical trial evaluating the efficacy of a multidisciplinary group-based telehealth intervention (HORIZONS) for improving quality of life, psychological distress, symptom burden, coping, and self-efficacy in hematopoietic stem cell transplant survivors living with chronic graft-versus-host disease. The study aims to...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will provide $402,401 to the University of Missouri System to conduct a pilot study on the feasibility and impact of a metacognitive strategy training (MCST) intervention for women with cancer-related cognitive impairment (CRCI) following breast cancer treatment. The study aims to examine the effects of MCST on cognitive performance, frontoparietal neural functioning, and functional...
- This $431,970 federal Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to develop a culturally-adapted, behavioral intervention called "South Asian Family Approaches to Disease (SAFAD)" to support self-management and alleviate stress, loneliness, and social isolation among South Asian breast cancer survivors and their family caregivers. The grant recipient, The Leland Stanford Junior University, will pursue two specific...
- The U.S. Department of Health and Human Services, National Institutes of Health (NIH) awarded a $406,080 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. The purpose of this 5-year grant, awarded on April 1, 2025, is to develop and test a novel daily, digital mindfulness-based intervention to reduce depressive symptoms in post-treatment cancer patients. The project will first create the...
The Project Grant award of $403,822, awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), will fund a pilot study to develop and test the "DESCANSO" cognitive behavioral therapy (CBT) intervention to treat the symptom cluster of depression, insomnia, and fatigue in Spanish-speaking Latino cancer patients. The study aims to culturally adapt the DESCANSO intervention, which combines CBT strategies to address insomnia, depression, and fatigue, and determine the feasibility of delivering it via telehealth to 100 Latino cancer patients across sites in New York and Puerto Rico. This pilot project will lay the groundwork for a larger clinical trial to evaluate the DESCANSO intervention's effectiveness in improving cancer-related symptoms and quality of life among this underserved population.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $403.8k | 8/13/25 |